According to the latest report by IMARC Group, titled "Companion Diagnostics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025," the global companion diagnostics market grew at a CAGR of around 15% during 2014-2019. Companion diagnostic is an in-vitro diagnostic testing kit, consisting of a combination of tests and therapies that are used for the development of personalized medicines. It is used to determine the personal molecular profile of patients that aids healthcare professionals in deciding upon the approach for their treatment. It also offers information regarding the safe and effective use of a certain corresponding drug or biological product. Its usage assists in delivering safe and effective medical care to patients by analyzing the responders and non-responders to the therapy and offering an in-depth understanding of the biology of their disease. Currently, these kits are widely used in oncology for drug discovery and delivering targeted therapies to individuals.
Request Free Sample Report: https://www.imarcgroup.com/companion-diagnostics-market/requestsample
We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.
Global Companion Diagnostics Market Trends:
The market is primarily driven by the increasing incidences of various forms of cancer on the global level. Companion diagnostics are widely used in advanced oncology healthcare for targeting biomarker identification and delivering targeted therapies to patients, thereby providing a thrust to the market growth. There has also been a significant increase in the demand for in-vitro diagnostics among the masses. This, along with the growing preference for personalized healthcare (PHC) and precision medicine in the healthcare sector, is facilitating the uptake of these diagnostics. Apart from this, there has been a rise in the utilization of targeted drugs and therapies for treating several infectious, cardiovascular, neurological, and inflammatory conditions. Coupled with the development of next-generation sequencing (NGS) and the increasing number of clinical trials, this is creating a positive outlook for the market. Additionally, several regulatory bodies, such as the US Food and Drug Administration (US FDA), have provided a defined structure for companion diagnostic development while encouraging the market players to conduct research activities in this field. The continual launch of new biomarkers, as well as the increasing number of collaborations between two or more companies for developing novel companion diagnostic products, is also providing an impetus to the market growth. The market is further driven by the rising application of companion diagnostics for analyzing the efficacy of COVID-19 drugs among patients undergoing oncology therapies. On account of the aforementioned factors, the market is anticipated to witness strong growth during 2020-2025.
• On the basis of the product and service, the market has been bifurcated into assays, kits and reagents, and software and services.
• Based on the technology, the market has been divided into immunohistochemistry (IHC), polymerase chain reaction (PCR), in-situ hybridization (ISH), real-time PCR (RT-PCR), gene sequencing and others.
• On the basis of the indication, the market has been classified into cancer (lung cancer, breast cancer, colorectal cancer, gastric cancer, melanoma and others), neurological diseases, infectious diseases, cardiovascular diseases and others.
• Based on the end user, the market has been categorized into pharmaceutical and biopharmaceutical companies, reference laboratories, contract research organizations, and others.
• On the geographical front, the market has been segregated into North America (the United States and Canada), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and others), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia and others), Latin America (Brazil, Mexico and others), and Middle East and Africa.
• The competitive landscape of the market has been studied in the report with the detailed profiles of the key players. Some of these players include Abbott Laboratories, Agilent Technologies, Inc., bioMérieux SA, Danaher Corporation, F. Hoffmann-La Roche Ltd, Myriad Genetics, Inc., Siemens Healthineers and Thermo Fisher Scientific Inc.
Explore Full Report with TOC & List of Figure: https://www.imarcgroup.com/companion-diagnostics-market
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
30 N Gould St Ste R
Sheridan, WY 82801 USA
Email: [email protected]
Tel No:(D) +91 120 433 0800 |
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800